Summary
123.38 -2.68(-2.13%)07/01/2024
Repligen Corp. (RGEN)
Repligen Corp. (RGEN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -2.20 | -0.35 | -17.92 | -32.63 | -31.15 | -13.13 | 43.38 | 996.71 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 123.38 | |
| Open | 125.94 | |
| High | 127.65 | |
| Low | 122.27 | |
| Volume | 481,095 | |
| Change | -2.78 | |
| Change % | -2.20 | |
| Avg Volume (20 Days) | 924,216 | |
| Volume/Avg Volume (20 Days) Ratio | 0.52 | |
| 52 Week Range | 110.46 - 211.13 | |
| Price vs 52 Week High | -41.56% | |
| Price vs 52 Week Low | 11.70% | |
| Range | -2.03 | |
| Gap Up/Down | -2.52 | |
Fundamentals | ||
| Market Capitalization (Mln) | 7,044 | |
| EBIDTA | 95,371,000 | |
| PE Ratio | 617.8148 | |
| PEG Ratio | 2.5900 | |
| WallStreet Target Price | 204.58 | |
| Book Value | 35.2890 | |
| Earnings Per Share | 0.2700 | |
| EPS Estimate Current Quarter | 0.3000 | |
| EPS Estimate Next Quarter | 0.3300 | |
| EPS Estimate Current Year | 1.4500 | |
| EPS Estimate Next Year | 2.0100 | |
| Diluted EPS (TTM) | 0.2700 | |
| Revenues | ||
| Profit Marging | 0.0244 | |
| Operating Marging (TTM) | 0.0134 | |
| Return on asset (TTM) | 0.0060 | |
| Return on equity (TTM) | 0.0076 | |
| Revenue TTM | 607,449,984 | |
| Revenue per share TTM | 10.8920 | |
| Quarterly Revenue Growth (YOY) | -0.1710 | |
| Quarterly Earnings Growth (YOY) | -0.9260 | |
| Gross Profit (TTM) | 455,706,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 617.8148 | |
| Forward PE | 119.0476 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.8608 | |
| Revenue Enterprise Value | 14.9384 | |
| EBITDA Enterprise Value | 71.1205 | |
| Shares | ||
| Shares Outstanding | 55,875,900 | |
| Shares Float | 52,050,072 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.09 | |
| Insider (%) | 6.58 | |
| Institutions (%) | 103.95 | |
06/24 08:35 EST - zacks.com
Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?
Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?
Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
06/21 08:22 EST - benzinga.com
Top 3 Health Care Stocks That Could Blast Off In June
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 3 Health Care Stocks That Could Blast Off In June
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
06/14 12:45 EST - zacks.com
Repligen (RGEN) Promotes CCO, Shares Fall on Leadership Change
Repligen (RGEN) appoints Olivier Loeillot as the company's new president and chief executive officer, effective from Sep 1, 2024. Stock falls on the news.
Repligen (RGEN) Promotes CCO, Shares Fall on Leadership Change
Repligen (RGEN) appoints Olivier Loeillot as the company's new president and chief executive officer, effective from Sep 1, 2024. Stock falls on the news.
06/13 07:00 EST - globenewswire.com
Repligen Announces CEO Transition Plan
Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024 Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024
Repligen Announces CEO Transition Plan
Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024 Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024
06/03 08:00 EST - businesswire.com
Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing
ST. PAUL, Minn. & WALTHAM, Mass.--(BUSINESS WIRE)--Ecolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of Purolite's DurA Cycle, a protein A chromatography resin for large-scale purification processes. This new affinity resin is being introduced at the BIO International Convention (BIO 2024), being held June 3-6 in San Diego. This l.
Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing
ST. PAUL, Minn. & WALTHAM, Mass.--(BUSINESS WIRE)--Ecolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of Purolite's DurA Cycle, a protein A chromatography resin for large-scale purification processes. This new affinity resin is being introduced at the BIO International Convention (BIO 2024), being held June 3-6 in San Diego. This l.
05/22 07:30 EST - globenewswire.com
Repligen Corporation to Present at Upcoming June Investor Conferences
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the following June investor conferences.
Repligen Corporation to Present at Upcoming June Investor Conferences
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the following June investor conferences.
05/07 07:30 EST - globenewswire.com
Repligen Corporation to Present at Upcoming May Investor Conferences
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.
Repligen Corporation to Present at Upcoming May Investor Conferences
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.
05/02 12:26 EST - zacks.com
Repligen (RGEN) Q1 Earnings Miss, Revenues Beat Estimates
Repligen's (RGEN) first-quarter 2024 earnings miss estimates while revenues beat the same.
Repligen (RGEN) Q1 Earnings Miss, Revenues Beat Estimates
Repligen's (RGEN) first-quarter 2024 earnings miss estimates while revenues beat the same.
05/01 09:51 EST - zacks.com
Repligen (RGEN) Misses Q1 Earnings Estimates
Repligen (RGEN) came out with quarterly earnings of $0.28 per share, missing the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.64 per share a year ago.
Repligen (RGEN) Misses Q1 Earnings Estimates
Repligen (RGEN) came out with quarterly earnings of $0.28 per share, missing the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.64 per share a year ago.
05/01 07:30 EST - globenewswire.com
Repligen Reports First Quarter 2024 Financial Results
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024. The company also reiterated its financial guidance for the full year 2024.
Repligen Reports First Quarter 2024 Financial Results
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024. The company also reiterated its financial guidance for the full year 2024.
04/17 07:30 EST - globenewswire.com
Repligen to Report First Quarter 2024 Financial Results
Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET
Repligen to Report First Quarter 2024 Financial Results
Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET
03/19 07:30 EST - globenewswire.com
Repligen Appoints Maggie A. Pax to Board of Directors
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen's board from eight to nine members. Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher Scientific, where, from 2016–2020, she served as Vice President, Strategy and Innovation for the clinical supply chain business. In this role, she led strategic planning, developed customer-facing innovation programs, and drove the business case for the company's multi-billion acquisition of Patheon, a leading biopharmaceutical contract manufacturer.
Repligen Appoints Maggie A. Pax to Board of Directors
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen's board from eight to nine members. Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher Scientific, where, from 2016–2020, she served as Vice President, Strategy and Innovation for the clinical supply chain business. In this role, she led strategic planning, developed customer-facing innovation programs, and drove the business case for the company's multi-billion acquisition of Patheon, a leading biopharmaceutical contract manufacturer.
03/04 12:46 EST - zacks.com
PBYI vs. RGEN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Puma Biotech (PBYI) and Repligen (RGEN). But which of these two companies is the best option for those looking for undervalued stocks?
PBYI vs. RGEN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Puma Biotech (PBYI) and Repligen (RGEN). But which of these two companies is the best option for those looking for undervalued stocks?
02/22 11:41 EST - zacks.com
Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/Y
Repligen's (RGEN) fourth-quarter 2023 earnings miss estimates and decline year over year. Stock declines.
Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/Y
Repligen's (RGEN) fourth-quarter 2023 earnings miss estimates and decline year over year. Stock declines.
02/21 14:35 EST - seekingalpha.com
Repligen Corporation (RGEN) Q4 2023 Earnings Call Transcript
Repligen Corporation (RGEN) Q4 2023 Earnings Call Transcript
Repligen Corporation (RGEN) Q4 2023 Earnings Call Transcript
Repligen Corporation (RGEN) Q4 2023 Earnings Call Transcript
02/21 09:46 EST - zacks.com
Repligen (RGEN) Lags Q4 Earnings and Revenue Estimates
Repligen (RGEN) came out with quarterly earnings of $0.33 per share, missing the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.68 per share a year ago.
Repligen (RGEN) Lags Q4 Earnings and Revenue Estimates
Repligen (RGEN) came out with quarterly earnings of $0.33 per share, missing the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.68 per share a year ago.
02/21 07:30 EST - globenewswire.com
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2023, covering the three- and twelve-month periods ended December 31, 2023. The company is also providing financial guidance for the full year 2024.
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2023, covering the three- and twelve-month periods ended December 31, 2023. The company is also providing financial guidance for the full year 2024.
02/07 07:30 EST - globenewswire.com
Repligen to Report Fourth Quarter and Full Year 2023 Financial Results
Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET
Repligen to Report Fourth Quarter and Full Year 2023 Financial Results
Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET
01/31 13:10 EST - zacks.com
Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?
Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?
Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
01/29 06:11 EST - zacks.com
Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?
Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?
Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.